Wedbush reiterates an 'Outperform' on BioMimetic Therapeutics (Nasdaq: BMTI), raises price target to $24.

Wedbush analyst says, "...We believe that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE